These include glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (Wegovy, Ozempic) and liraglutide (Saxenda), as well as tirzepatide (Zepbound, Mounjaro), which is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist
According to recent research compiled in AagingBase, there are currently 282 experimentally validated anti-aging peptides drawn from 54 research articles and 236 patents
Rises in the concentration of the main antioxidant of the body, glutathione reduced
This triple activation is not just marketing language
They should not be treated as though participants were directly randomised between Mounjaro and the Wegovy pill in one simple comparison
[1] [2] These medicines include semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and exenatide (Byetta, Bydureon), among others